| Market Capitalization (Millions $) |
590 |
| Shares
Outstanding (Millions) |
53 |
| Employees |
16 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-47 |
| Cash Flow (TTM) (Millions $) |
-41 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Sagimet Biosciences Inc. is a biopharmaceutical company that specializes in developing innovative therapies for the treatment of chronic liver diseases and metabolic disorders. The company focuses on creating targeted therapies to address the unmet medical needs of patients suffering from conditions such as non-alcoholic steatohepatitis (NASH) and type 2 diabetes.
Sagimet Biosciences utilizes a combination of in-depth research, advanced technologies, and state-of-the-art drug discovery platforms to develop novel drug candidates. Their research and development efforts are grounded in a deep understanding of the underlying disease mechanisms and the identification of potential therapeutic targets.
The company's flagship product candidate, TVB-2640, is an orally administered small molecule designed to inhibit a key enzyme involved in the synthesis of lipids. By reducing lipid synthesis and improving metabolism, TVB-2640 has the potential to treat liver diseases associated with metabolic disorders.
Sagimet Biosciences is committed to advancing the field of liver disease and metabolic disorder therapeutics through strategic partnerships, rigorous clinical trials, and collaborations with leading researchers in the field. Their ultimate goal is to develop safe and effective therapies that improve the lives of patients suffering from chronic liver diseases and metabolic disorders.
Company Address: 155 Bovet Road San Mateo 94402 CA
Company Phone Number: 561-8600 Stock Exchange / Ticker: NASDAQ SGMT
|
2.01%